Pharma company rebrands to Stablecoin Development Corp, drops $134M on SKY tokens

A company that used to sell antimicrobial eye care products now owns almost one-tenth of the Sky protocol’s governance token. That sentence is not a joke.

NovaBay Pharmaceuticals, trading under the ticker NBY, has rebranded itself as Stablecoin Development Corp (SDEV) after closing a $134M private placement and scooping up 2.06 billion SKY tokens — roughly 8.78% of the token’s entire circulating supply. The haul is currently valued at approximately $147M.

From lab coats to lockups

The company accumulated its position partly through open-market purchases at an average price of around $0.065 per token. It’s now staking the holdings for yields that management says exceed 10% annually.

That staking activity has already generated 26.6 million SKY tokens in rewards. In English: the treasury is printing more governance power just by sitting there.

Shares of the newly christened SDEV rose about 5% on the news. Modest, but not bad for a company whose previous claim to fame was an FDA-cleared wound care solution called NovaBay.

The pivot follows a growing trend of publicly traded companies reinventing themselves as crypto treasury vehicles. MicroStrategy — now rebranded as Strategy — pioneered this playbook with Bitcoin. Others have tried copying it with varying degrees of success and self-awareness. SDEV is betting the same logic applies to a DeFi governance token, which is a considerably spicier proposition.

Why SKY, and why this much of it

Sky (formerly MakerDAO) is the protocol behind USDS, a decentralized stablecoin. Holding SKY tokens means holding votes on how that stablecoin ecosystem operates — everything from collateral requirements to fee structures.

Here’s the thing: when a single entity controls nearly 9% of a governance token’s supply, it doesn’t just earn yield. It earns influence.

There’s a plausible strategic angle buried under the headline absurdity. A pharma-adjacent company with deep governance sway over a stablecoin protocol could theoretically push USDS toward regulated healthcare payment rails. Think clinical trial disbursements, insurance settlements, or tokenized pharmaceutical supply chain finance. Whether SDEV actually pursues that vision or simply treats SKY as a yield farm with a stock ticker remains to be seen.

The concentration risk is hard to ignore, though. SKY is a governance token for a DeFi protocol — not exactly the most liquid or stable asset class. A position worth $147M representing 8.78% of supply means exits would be painful. Any significant sell pressure from SDEV would crater the token’s price well before the company could fully unwind.

Lockup terms on the staked tokens add another layer of illiquidity. Management is essentially betting that SKY’s value holds or appreciates over whatever vesting timeline they’ve committed to. If DeFi governance tokens enter another prolonged winter, SDEV shareholders are along for the ride.

What this means for investors

The bull case is straightforward: staking yields above 10% dwarf anything NovaBay was generating in the pharmaceutical business. The company’s legacy operations were small, unprofitable, and going nowhere. Pivoting to a crypto treasury strategy at least gives the stock a narrative catalyst and a measurable income stream.

The bear case is equally straightforward: this is a micro-cap company concentrating its entire balance sheet in a single volatile token with governance-level exposure to DeFi regulatory risk. If the SEC decides governance tokens are securities, or if Sky’s protocol economics change unfavorably, SDEV has no fallback business to cushion the blow.

For SKY holders, the implications are mixed. Having a publicly traded company as a major stakeholder could lend legitimacy and create buying pressure. But it also introduces a whale with corporate obligations — quarterly earnings calls, shareholder lawsuits, board decisions — that don’t always align with decentralized governance ideals.

Watch whether SDEV actually submits governance proposals aimed at healthcare use cases. That would signal this is more than a yield play. If the company stays silent on governance, it’s just a leveraged bet with extra steps.

Bottom line: A pharma company owning 9% of a DeFi governance token is either the most creative corporate pivot of 2025 or the setup for a cautionary tale. The staking math works today. Whether it survives contact with a real market downturn is another question entirely.